Publication

From evidence based medicine to mechanism based medicine: Reviewing the role of pharmacogenetics

Wilffert, B., Swen, J., Mulder, H., Touw, D., Maitland-Van der Zee, A-H., Deneer, V. & KNMP Working Grp Pharmacogenetics, Jun-2013, In : International Journal of Clinical Pharmacy. 35, 3, p. 369-375 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Wilffert, B., Swen, J., Mulder, H., Touw, D., Maitland-Van der Zee, A-H., Deneer, V., & KNMP Working Grp Pharmacogenetics (2013). From evidence based medicine to mechanism based medicine: Reviewing the role of pharmacogenetics. International Journal of Clinical Pharmacy, 35(3), 369-375. https://doi.org/10.1007/s11096-010-9446-1

Author

Wilffert, Bob ; Swen, Jesse ; Mulder, Hans ; Touw, Daan ; Maitland-Van der Zee, Anke-Hilse ; Deneer, Vera ; KNMP Working Grp Pharmacogenetics. / From evidence based medicine to mechanism based medicine : Reviewing the role of pharmacogenetics. In: International Journal of Clinical Pharmacy. 2013 ; Vol. 35, No. 3. pp. 369-375.

Harvard

Wilffert, B, Swen, J, Mulder, H, Touw, D, Maitland-Van der Zee, A-H, Deneer, V & KNMP Working Grp Pharmacogenetics 2013, 'From evidence based medicine to mechanism based medicine: Reviewing the role of pharmacogenetics' International Journal of Clinical Pharmacy, vol. 35, no. 3, pp. 369-375. https://doi.org/10.1007/s11096-010-9446-1

Standard

From evidence based medicine to mechanism based medicine : Reviewing the role of pharmacogenetics. / Wilffert, Bob; Swen, Jesse; Mulder, Hans; Touw, Daan; Maitland-Van der Zee, Anke-Hilse; Deneer, Vera; KNMP Working Grp Pharmacogenetics.

In: International Journal of Clinical Pharmacy, Vol. 35, No. 3, 06.2013, p. 369-375.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Wilffert B, Swen J, Mulder H, Touw D, Maitland-Van der Zee A-H, Deneer V et al. From evidence based medicine to mechanism based medicine: Reviewing the role of pharmacogenetics. International Journal of Clinical Pharmacy. 2013 Jun;35(3):369-375. https://doi.org/10.1007/s11096-010-9446-1


BibTeX

@article{4e3cd3e0601b4b0a9ced29dce0b2c158,
title = "From evidence based medicine to mechanism based medicine: Reviewing the role of pharmacogenetics",
abstract = "Aim of the review The translation of evidence based medicine to a specific patient presents a considerable challenge. We present by means of the examples nortriptyline, tramadol, clopidogrel, coumarins, abacavir and antipsychotics the discrepancy between available pharmacogenetic information and its implementation in daily clinical practice. Method Literature review. Results A mechanism based approach may be helpful to personalize medicine for the individual patient to which pharmacogenetics may contribute significantly. The lack of consistency in what we accept in bioequivalence and in pharmacogenetics of drug metabolising enzymes is discussed and illustrated with the example of nortriptyline. The impact of pharmacogenetics on examples like tramadol, clopidogrel, coumarins and abacavir is described. Also the present status of the polymorphisms of 5-HT2A and C receptors in antipsychotic-induced weight gain is presented as a pharmacodynamic example with until now a greater distance to clinical implementation. Conclusion The contribution of pharmacogenetics to tailor-made pharmacotherapy, which especially might be of value for patients deviating from the average, has not yet reached the position it seems to deserve.",
keywords = "Drug metabolising enzymes, Mechanism based medicine, Pharmacodynamics, Pharmacogenetics, Pharmacokinetics, INDUCED WEIGHT-GAIN, HTR2C GENE POLYMORPHISMS, 5-HT2C RECEPTOR GENE, PHENYTOIN TOXICITY, THE-759C/T POLYMORPHISM, PSYCHIATRIC-PATIENTS, CYP2C POLYMORPHISMS, ANALGESIC TRAMADOL, METABOLIC SYNDROME, CLINICAL-PRACTICE",
author = "Bob Wilffert and Jesse Swen and Hans Mulder and Daan Touw and {Maitland-Van der Zee}, Anke-Hilse and Vera Deneer and {KNMP Working Grp Pharmacogenetics}",
year = "2013",
month = "6",
doi = "10.1007/s11096-010-9446-1",
language = "English",
volume = "35",
pages = "369--375",
journal = "International Journal of Clinical Pharmacy",
issn = "2210-7703",
publisher = "SPRINGER",
number = "3",

}

RIS

TY - JOUR

T1 - From evidence based medicine to mechanism based medicine

T2 - Reviewing the role of pharmacogenetics

AU - Wilffert, Bob

AU - Swen, Jesse

AU - Mulder, Hans

AU - Touw, Daan

AU - Maitland-Van der Zee, Anke-Hilse

AU - Deneer, Vera

AU - KNMP Working Grp Pharmacogenetics

PY - 2013/6

Y1 - 2013/6

N2 - Aim of the review The translation of evidence based medicine to a specific patient presents a considerable challenge. We present by means of the examples nortriptyline, tramadol, clopidogrel, coumarins, abacavir and antipsychotics the discrepancy between available pharmacogenetic information and its implementation in daily clinical practice. Method Literature review. Results A mechanism based approach may be helpful to personalize medicine for the individual patient to which pharmacogenetics may contribute significantly. The lack of consistency in what we accept in bioequivalence and in pharmacogenetics of drug metabolising enzymes is discussed and illustrated with the example of nortriptyline. The impact of pharmacogenetics on examples like tramadol, clopidogrel, coumarins and abacavir is described. Also the present status of the polymorphisms of 5-HT2A and C receptors in antipsychotic-induced weight gain is presented as a pharmacodynamic example with until now a greater distance to clinical implementation. Conclusion The contribution of pharmacogenetics to tailor-made pharmacotherapy, which especially might be of value for patients deviating from the average, has not yet reached the position it seems to deserve.

AB - Aim of the review The translation of evidence based medicine to a specific patient presents a considerable challenge. We present by means of the examples nortriptyline, tramadol, clopidogrel, coumarins, abacavir and antipsychotics the discrepancy between available pharmacogenetic information and its implementation in daily clinical practice. Method Literature review. Results A mechanism based approach may be helpful to personalize medicine for the individual patient to which pharmacogenetics may contribute significantly. The lack of consistency in what we accept in bioequivalence and in pharmacogenetics of drug metabolising enzymes is discussed and illustrated with the example of nortriptyline. The impact of pharmacogenetics on examples like tramadol, clopidogrel, coumarins and abacavir is described. Also the present status of the polymorphisms of 5-HT2A and C receptors in antipsychotic-induced weight gain is presented as a pharmacodynamic example with until now a greater distance to clinical implementation. Conclusion The contribution of pharmacogenetics to tailor-made pharmacotherapy, which especially might be of value for patients deviating from the average, has not yet reached the position it seems to deserve.

KW - Drug metabolising enzymes

KW - Mechanism based medicine

KW - Pharmacodynamics

KW - Pharmacogenetics

KW - Pharmacokinetics

KW - INDUCED WEIGHT-GAIN

KW - HTR2C GENE POLYMORPHISMS

KW - 5-HT2C RECEPTOR GENE

KW - PHENYTOIN TOXICITY

KW - THE-759C/T POLYMORPHISM

KW - PSYCHIATRIC-PATIENTS

KW - CYP2C POLYMORPHISMS

KW - ANALGESIC TRAMADOL

KW - METABOLIC SYNDROME

KW - CLINICAL-PRACTICE

U2 - 10.1007/s11096-010-9446-1

DO - 10.1007/s11096-010-9446-1

M3 - Article

VL - 35

SP - 369

EP - 375

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

SN - 2210-7703

IS - 3

ER -

ID: 13986929